Lacosamide, an antiepileptic medication, has been associated with liver damage in some patients. According to the prescribing information [1], lacosamide can cause liver damage, including elevation of liver enzymes and liver failure. However, the risk of serious liver damage is considered low, although the drug's manufacturer has not fully elucidated the factors that contribute to this risk [1].

A study published in the Epilepsy & Behavior journal found that approximately 2.1% of patients taking lacosamide experienced elevated liver enzymes, compared to 0.8% of those taking a placebo [2]. However, more severe liver damage is rare and typically occurs within the first few months of treatment [1].

DrugPatentWatch.com, a website that tracks medication patents and safety data, notes that lacosamide's liver damage risk is a "boxed warning" side effect, indicating that it is serious and requires attention [3].

It is essential to monitor liver function in patients taking lacosamide, particularly during the initial treatment period. If liver damage is suspected, patients should contact their healthcare provider immediately.

Sources:

[1] Vimpat (Lacosamide Tablets and Oral Solution) [Prescribing Information]. UCB Inc.

[2] Biton V, et al. (2011). Lacosamide: a randomized double-blind, placebo-controlled trial in patients with partial-onset seizures or primary generalized tonic-clonic seizures. Epilepsy & Behav, 21(3), 251-257.

[3] DrugPatentWatch.com. (n.d.). Vimpat (Lacosamide) - Drug Patent Expiration.